Decades of research and the emergence of new therapies has led to an appreciation for the role of the immune system in the evolution of colorectal cancer. A paradigm shift is occurring in the assessment of tumor-infiltrating lymphocytes (TILs) for prognostication and prediction of benefit from adjuvant therapies, with the emergence of a new clinical biomarker, called the Immunoscore®.
If your tumor is stage II:
Your tumor is localized. Based on the TNM (staging) classification and clinicopathological (exam and lab results) parameters, your doctor may recommend surgery alone or chemotherapy in addition to surgery. Using Immunoscore®, you will benefit from knowing your biology, which helps in choosing the best personalized therapeutics strategy.
Immunoscore® should be considered after surgery and before making a decision on treatment (chemotherapy or not).
If your cancer is stage III:
Your cancer is more advanced, which means you will need the help of chemotherapy, to fight against the cancer. Immunoscore® will help your doctor determine the most appropriate duration of chemotherapy for your situation.
Immunoscore® can be considered after surgery, to determine the optimal treatment (FOLFOX) duration (3 or 6 months of FOLFOX) and avoid unnecessary toxicities.
Immunoscore® is available all around the world and can be prescribed by oncologists.
It has been used in clinical routine practice in more than 25 countries.
Therefore, the immune response has been included in the WHO recommendations as a desirable and essential diagnostic criterion for colorectal cancer in addition to the histological parameter.
Questions about Immunoscore? Email [email protected] or call (804) 944-2000.